

GOSH Extracranial germ cell tumour August 15

Diagnosis		Place of delivery									
		PTC	Safari Day care	Low Risk	POSCU Level 1	POSCU Level 2	POSCU Level 3	Chemocare	Tx Guideline	Review date	Comments
<b>Non CNS Germ cell tumour</b>											
JEB	Carboplatin, Etoposide, bleomycin	✓						N	CCLG Interim guideline for the treatment of extracranial germ cell tumours Jan 2011	N/A	
<b>Non CNS Germ cell tumour - relapsed</b>											
VEIP	Vinblastine, Etoposide, Ifosfamide, Cisplatin,	✓						Y	CCLG Interim guideline for the treatment of extracranial germ cell tumours Jan 2011	N/A	

Diagnosis		Place of delivery									
		PTC	Safari Day care	Low Risk	POSCU level 1	POSCU Level 2	POSCU Level 3	Chemocare	Tx Guideline	Review date	Comments
<b>Acute Lymphoblastic Leukaemia Interim Guidelines 2011</b>											
<b>Regimen A</b>											
<b>induction</b>	Vincristine, Pegaspargase, Dexamethasone	✓ (until 1st discharge)	✓		✓ from D15	✓ from D15	✓ from D15	Y	ALL 2011 Interim guidelines V4	N/A	
<b>consolidation</b>	6 Mercaptopurine,	✓	✓					Y			
<b>Interim MX</b>	Vincristine, 6 MP, MTX, dexamethasone	✓	✓		✓	✓	✓	Y			
<b>Delayed intensification Day1</b>	Vincristine, Doxorubicin Dexamethasone, Pegaspargase,	✓	✓		✓ day 2 & 4	✓ day 2 & 4	✓	Y			
Day 8	Vincristine, Doxorubicin	✓	✓			✓	✓	Y			
Day 15	Vincristine, Doxorubicin Dexamethasone	✓	✓			✓	✓	Y			
Day 29	cyclophosphamide, cytarabine, 6MP	✓	✓	✓ day 30-33	✓ day 30-33	✓ day 30-33	✓	Y			
Day 36	cytarabine	✓	✓	✓	✓	✓	✓	Y			
<b>Maintenance</b>	Vincristine, 6 MP, MTX, dexamethasone	✓	✓	✓	✓	✓	✓	Y			
<b>Intrathecal MTX</b>		✓	✓					Y			

Regimen B											
<b>induction</b>	Vincristine, Pegaspargase, Dexamethasone Daunorubicin	✓ (until 1st discharge)	✓		✓ day 30	✓ day 30	✓ from D15	Y	ALL 2011 Interim guidelines V4	N/A	
<b>BFM consolidation</b>	Cyclophosphamide, cytarabine, 6 Mercaptopurine,	✓	✓	✓ cytarabine only	✓ cytarabine only	✓ cytarabine only	✓	Y			
<b>Interim MX</b>	Vincristine, 6 MP, MTX, dexamethasone	✓	✓		✓ day 2&30	✓ day 2&30	✓	Y			
<b>Delayed intensification Day1</b>	Vincristine, Doxorubicin Dexamethasone, Pegaspargase,	✓	✓		✓ day 2 & 4	✓ day2& 4	✓	Y			
Day 8	Vincristine, Doxorubicin	✓	✓			✓	✓	Y			
Day 15	Vincristine, Doxorubicin Dexamethasone	✓	✓			✓	✓	Y			
Day 29	cyclophosphamide, cytarabine, 6MP	✓	✓	✓ day 30-32	✓ day 30-33	✓ day 30-33	✓	Y			
Day 36	cytarabine	✓	✓	✓	✓	✓	✓	Y			
<b>Maintenance</b>	Vincristine, 6 MP, MTX, dexamethasone	✓	✓		✓	✓	✓	Y			
<b>Intrathecal MTX</b>		✓	✓								

Regimen C								
<b>induction</b>	Vincristine, Pegasparginase, Dexamethasone, Daunorubicin	✓ (until 1st discharge)	✓ from D15		✓ day 29	✓ day 29	✓ from D15	Y
<b>augmentd BFM consolidation Day 1-28</b>	Vincristine, Pegasparginase Cyclophosphamide, cytarabine, 6 Mercaptopurine	✓	✓	✓ cytarabine,	✓ cytarabine, vinc & Oncaspar	✓ cytarabine, vinc & Oncaspar	✓ cytar, vinc & Oncaspar	Y
Day 29-63	Cyclophosphamide, cytarabine, 6 Mercaptopurine Vincristine Pegasparginase	✓	✓	✓ Cytarabine	✓ Cytarabine, vinc & Oncaspar	✓ cytarabine, vinc & Oncaspar	✓ cytar, vinc & Oncaspar	Y
<b>Escalating Cappizzi MX</b>	Vincristine, Methotrexate, Pegasparginase Day 1,2, 3, 12, 22, 23, 32, 42	✓	✓		✓ vinc & Onc/ Erwi	✓ vinc & Onc/ Erwi	✓	Y
<b>Delayed intensification Day 1</b>	Vincristine, Doxorubicin Dexamethasone, Pegasparginase,	✓	✓		✓ day 2 & 4	✓ day2& 4	✓	Y
Day 8	Vincristine, Doxorubicin	✓	✓			✓	✓	Y
Day 15	Vincristine, Doxorubicin Dexamethasone	✓	✓			✓	✓	Y
Day 29	Cyclophosphamide, 6MP, Cytarabine, Vincristine Pegasparginase	✓	✓	✓ day 30-33 cytarabine	✓ day 30-33 cyt and Onca	✓ day 30-33 cyt and Onca	✓	Y
Day 35	Cytarabine	✓	✓	✓	✓	✓	✓	Y
Day 43	Vincristine, Pegasparginase	✓	✓					Y
Day 50	Vincristine	✓			✓	✓	✓	Y
<b>Maintenance cycle</b>	Vincristine, Dexamethasone, 6MP, MTX)	✓	✓		✓	✓	✓	Y
<b>Intrathecal MTX</b>		✓	✓					Y

ALL 2011 Interim guidelines V4

N/A

ALL 2011 Trial											
Regimen A IMPs highlighted in red .May be given at POSCUs activated as trial sites											
<b>induction</b>	Vincristine,Pegaspargase, Dexamethasone	✓(until 1st discharge)	✓		✓from D15	✓from D15	✓from D15	Y	UKALL 2011 V3 1st Oct 2013	N/A	
<b>consolidation</b>	6 Mercaptopurine,	✓	✓					Y			
<b>Interim MX or</b>	Vincristine, 6 MP, MTX, dexamethasone	✓	✓		✓	✓	✓	Y			
<b>Protocol M</b>	IV Methotrexate, 6MP	✓						Y			
<b>Delayed intensification Day1</b>	Vincristine, Doxorubicin Dexamethasone,	✓	✓		✓day 2 & 4	✓day 2 & 4	✓	Y			
Day 8	Vincristine, Doxorubicin	✓	✓			✓	✓	Y			
Day 15	Vincristine, Doxorubicin Dexamethasone	✓	✓			✓	✓	Y			
Day 29	cyclophosphamide, cytarabine, 6MP	✓	✓	✓ day 30-32	✓ day 30-33	✓ day 30-33	✓	Y			
Day 36	cytarabine	✓	✓	✓	✓	✓	✓	Y			
<b>Maintenance or</b>	Vincristine, 6 MP, MTX, dexamethasone, IT MTX	✓	✓		✓ Except ITMTX	✓ Except ITMTX	✓ Except ITMTX	Y			
<b>Maintenance or</b>	6 MP, MTX, IT MTX	✓	✓					Y			
<b>Maintenance or</b>	Vincristine, 6 MP, MTX, dexamethasone,	✓	✓					Y			
<b>Maintenance or</b>	6 MP, MTX,	✓	✓					Y			
<b>Intrathecal MTX</b>		✓	✓					Y			

Regimen B IMPs highlighted in red. May be given at POSCUs activated as trial sites												
<b>Induction</b>	Vincristine, Pegaspargase, Daunorubicin, <b>Dexamethasone</b>	✓ (until 1st discharge)	✓			✓ from D14 excludes daunorubicin	✓ from D14 excludes daunorubicin	✓ from D14 excludes daunorubicin	Y	UKALL 2011 V3 1st Oct 2013	N/A	
<b>BFM consolidation</b>	Cyclophosphamide, cytarabine, 6 Mercaptopurine,	✓	✓	✓ cytarabine only	✓ cytarabine only	✓ cytarabine only	✓	Y				
<b>Interim MX or</b>	<b>Vincristine, 6 MP, MTX, dexamethasone</b>	✓	✓		✓	✓	✓	Y				
<b>Protocol M</b>	<b>IV Methotrexate, 6MP</b>	✓						Y				
<b>Delayed intensification Day1</b>	Vincristine, Doxorubicin Dexamethasone, Pegaspargase,	✓	✓		✓ day 2 & 4	✓ day 2 & 4	✓	Y				
Day 8	Vincristine, Doxorubicin	✓	✓			✓	✓	Y				
Day 15	Vincristine, Doxorubicin Dexamethasone	✓	✓			✓	✓	Y				
Day 29	cyclophosphamide, cytarabine, 6MP	✓	✓	✓ day 30-32	✓ day 30-33	✓ day 30-33	✓	Y				
Day 36	cytarabine	✓	✓	✓	✓	✓	✓	Y				
<b>Maintenance or</b>	<b>Vincristine, 6 MP, MTX, dexamethasone, IT MTX</b>	✓	✓		✓ Except ITMTX	✓ Except ITMTX	✓ Except ITMTX	Y				
<b>Maintenance or</b>	6 MP, MTX, <b>IT MTX</b>	✓	✓					Y				
<b>Maintenance or</b>	<b>Vincristine, 6 MP, MTX, dexamethasone,</b>	✓	✓		✓	✓	✓	Y				
<b>Maintenance or</b>	6 MP, MTX,	✓	✓					Y				
<b>Intrathecal MTX</b>		✓	✓					Y				

Regimen C IMPs highlighted in red. May be given at POSCUs activated as trial sites									
<b>Induction</b>	Vincristine, Pegaspargase, Daunorubicin, <b>Dexamethasone</b>	✓ (until 1st discharge)	✓		✓ from D14 excludes daunorubicin	✓ from D14 excludes daunorubicin	✓ from D14 excludes daunorubicin	Y	
<b>Augmentd BFM consolidation Day 1-28</b>	Vincristine, Pegasparaginase Cyclophosphamide, cytarabine, 6 Mercaptopurine	✓	✓	✓ cytarabine,	✓ cytarabine, vinc & Oncaspar	✓ cytarabine, vinc & Oncaspar	✓ cytar, vinc & Oncaspar	Y	
Day 29-63	Cyclophosphamide, cytarabine, 6 Mercaptopurine Vincristine Pegaspargase	✓	✓	✓ Cytarabine,	✓ Cytarabine, vinc & Oncaspar	✓ cytarabine, vinc & Oncaspar	✓ cytar, vinc & Oncaspar	Y	
<b>Escalating Cappizzi MX</b>	<b>Vincristine, Methotrexate, Pegaspargase Day 1, 2, 3, 12, 22, 23, 32, 42</b>	✓	✓					Y	
<b>Protocol MA</b>	<b>IV Methotrexate, 6MP, pegaspargase</b>	✓						Y	
<b>Delayed intensification Day1</b>	Vincristine, Doxorubicin Dexamethasone, Pegaspargase,	✓	✓		✓ day 2 & 4	✓ day 2 & 4	✓	Y	UKALL 2011 V3 1st Oct 2013
Day 8	Vincristine, Doxorubicin	✓	✓			✓	✓	Y	
Day 15	Vincristine, Doxorubicin Dexamethasone,	✓	✓			✓	✓	Y	
Day 29	cyclophosphamide, cytarabine, 6MP	✓	✓	✓ day 30-32	✓ day 30-33	✓ day 30-33	✓	Y	
Day 36	cytarabine	✓	✓	✓	✓	✓	✓	Y	
<b>Maintenance or</b>	<b>Vincristine, 6 MP, MTX, dexamethasone, IT MTX</b>	✓	✓	✓	✓ Except ITMTX	✓ Except ITMTX	✓ Except ITMTX	Y	
<b>Maintenance or</b>	6 MP, MTX, <b>IT MTX</b>	✓	✓					Y	
<b>Maintenance or</b>	<b>Vincristine, 6 MP, MTX, dexamethasone,</b>	✓	✓	✓	✓	✓	✓	Y	
<b>Maintenance Intrathecal MTX</b>	6 MP, MTX,	✓	✓					Y	
		✓	✓					Y	

GOSH Approved regimens  
 ALL August 2015  
 Approved by Dr Sujith Samarasinghe on behalf of the Haematology MDT

GOSH Approved Regimens  
 ALL August 2015  
 Approved by Dr Sujith Samarasinghe of behalf of the Haematology MDT

Diagnosis		Place of delivery							Chemocare	Tx Guideline	Review date	Comments
		PTC	Safari Day care	Low Risk	POSCU Level 1	POSCU Level 2	POSCU Level 3					
<b>Interfant 06 trial</b>												
<b>IMPs randomised patients only</b>												
In the 1B regimen - cyclophosphamide, cytarabine, mercaptopurine and intrathecal hydrocortisone, cytarabine and methotrexate												
In the ADE+MAE regimen - cytarabine, etoposide, daunorubicin, mitoxantrone and intrathecal hydrocortisone, cytarabine and methotrexate.												
<b>Induction</b>	Day 1-7	Prednisolone, IT MTX/Hc	✓							Y	Interfant 06 V6 17th September 2014	N/A
	Day 8-35	Dexamethasone, Vincristine, Cytarabine, Daunorubicin, Medac Asp, IT Cytar/MTX/ Hc	✓					✓		Y		
<b>a) Protocol 1B</b>	Day 36-64	Cyclo, 6 MP, cytar, IT Cytar/Hc/MTX	✓	✓	✓ Cytar	✓ Cytar	✓ Cytar	✓ Cytar		Y		
<b>b1) ADE</b>	Day 36	Cytar, Dauno, Etop, IT Cytar/Hc	✓							Y		
<b>b2) MAE</b>	Day 57 (approx)	Cytar, Mitox, Etop, IT MTX/Hc	✓							Y		
<b>MARMA</b>	Day 1-2, 8-9	HD MTX, IT MTX/Hc, 6MP	✓							Y		
	Day 15-23	HD cytar, Oncaspar	✓							Y		
<b>a) OCTADAD</b>	Day 1-28	Dex, tioguanine, vinc, dauno, Oncaspar, cytar, IT Cytar/Hc	✓	✓	✓ Cytar	✓ Cytar	✓ Cytar	✓		Y		
	Day 36-49	Tiog, cytar, cyclo	✓	✓	✓ Cytar	✓ Cytar	✓ Cytar	✓		Y		
<b>b) OCTADA</b>	Day 1-28	Dex, tioguanine, vinc, Oncaspar, cytar, IT Cytar/Hc	✓	✓	✓ Cytar	✓ Cytar	✓ Cytar	✓		Y		
	Day 36-49	Tiog, cytar, cyclo	✓	✓	✓ Cytar	✓ Cytar	✓ Cytar	✓		Y		
<b>Maintenance</b>		6-MP, MTX,	✓	✓				✓		Y		
Intrathecal therapy		IT MTX/Hc/Cytar	✓	✓						Y		

Diagnosis		Place of delivery									Review date	Comments
		PTC	Safari Day care	Low Risk	POSCU Level 1	POSCU Level 2	POSCU Level 3	Chemocare	Tx Guideline			
<b>Ph+ve Acute Lymphoblastic Leukaemia - Treatment Guideline</b>												
Phase 1B Induction Day 1-29	Cyclophosphamide 6MP, imatinib, cytarabine	✓	✓	✓ cytarabine only	✓ cytarabine only	✓ cytarabine only	✓	Y	EsPhALL v 5.1 with GOSH amendments 25/03/15	N/A	If intolerant to imatinib, use dasatinib.	
Consolidation Block HR 1	MTX, dexamethasone, vincristine, cyclophosphamide, cytarabine, pegaspargase, imatinib	✓						Y				
Consolidation block HR2	dexamethasone, MTX, videsine, ifosfamide, Daunorubicin, Pegaspargase, Imatinib	✓						Y				
Consolidation block HR 3	dexamethasone cytarabine etoposide, pegaspargase, imatinib	✓						Y				
Delayed re-intensification block Phase IIA	Vincristine, Dexamethasone, Doxorubicin, Pegaspargase, imatinib	✓	✓				✓	Y				
Delayed re-intensification block Phase IIB	Cyclophosphamide, Tioguanine, imatinib, cytarabine	✓	✓	✓ cytarabine only	✓ cytarabine only	✓ cytarabine only	✓	Y				
Interim maintenance/ Cranial irradiation	Mercaptopurine, Methotrexate, imatinib	✓	✓		✓	✓	✓	Y				
Maintenance	Mercaptopurine, Methotrexate, Vincristine, Dexamethasone, imatinib	✓	✓		✓	✓	✓	Y				
Intrathecal therapy		✓	✓					Y				

GOSH Relapsed/Refractory ALL  
August 2015

Diagnosis		Place of delivery							Tx Guideline	Review date	Comments
		PTC	Safari Day care	Low Risk	POSCU Level 1	POSCU Level 2	POSCU Level 3	Chemocare			
<b>Relapsed Acute Lymphoblastic Leukaemia</b>											
<b>Phase 1</b> Induction Weeks 1-4	Vincristine, Dexamethasone Mitoxantrone, Pegaspargase	✓						Y	R3 Version 5 Amendment 4 23rd May 2009 with GOSH		
<b>Phase 2</b> Consolidation week 5	Vincristine, Dexamethasone	✓	✓		✓	✓	✓	Y			
week 6	MTX, pegaspargase	✓						Y			
week 7	etoposide, cyclophosphamide	✓					✓	Y			
<b>Phase 3</b> Intensification week 9	Erwinia Asparaginase, dexamethasone, cytarabine, vincristine	✓						Y			
week 10	Erwinia Asparaginase, cytarabine	✓						Y			
week 12	MTX, Erwinia asparaginase	✓						Y			
<b>Phase 4 (FLAD)</b>	Fludarabine, Cytarabine Daunoxome	✓						Y			
<b>Phase 5 (IM) with CNS irradiation</b> week 14-16	Dexamethasone, 6MP, Vincristine,	✓	✓					N			
week 17	6MP,HD po MTX	✓	✓					N			
week 18-19	6MP, MTX	✓	✓					N			
week 20 Relapsed/Refractory ALL August 2015	Etoposide, cyclophosphamide, Cytarabine, MTX Tioguanine	✓	✓	✓ cytara bine only	✓ cytarabine only	✓ cytarabine only	✓ cytarabine only	N			

GOSH Relapsed/Refractory ALL  
August 2015

week 21	Etoposide, cyclophosphamide, cytarabine	✓	✓	cytara bine only	✓ cytarabine only	✓ cytarabine only	✓ cytarabine only	N
week 22-24	Dexamethasone, 6MP, MTX, Vincristine	✓	✓					N
week 25	6MP,HD po MTX	✓	✓					N
week 26-7	6MP, MTX	✓	✓					N
week 28	Etoposide, cyclophosphamide, Cytarabine, MTX Tioguanine	✓	✓	✓ cytara bine only	✓ cytarabine only	✓ cytarabine only	✓ cytarabine only	N
week 29	Etoposide, cyclophosphamide, cytarabine	✓	✓	cytara bine only	✓ cytarabine only	✓ cytarabine only	✓ cytarabine only	N

R3 Version 5  
Amendment 4  
23rd May  
2009 with  
GOSH  
frontsheet

N/A

GOSH Relapsed/Refractory ALL  
August 2015

<b>Phase 5 (IM) no CNS irradiation</b> week 14-15	Dexamethasone, 6MP, Vincristine,	✓	✓	✓ vinc & dex	✓ vinc & dex	✓ vinc & dex	✓ vinc & dex	N
week 17	6MP,HD po MTX	✓	✓					N
week 18-19	6MP, MTX	✓	✓					N
week 20	Etoposide, cyclophosphamide, Cytarabine, MTX Tioguanine	✓	✓	✓ cytara bine only	✓ cytarabine only	✓ cytarabine only	✓ cytarabine only	N
week 21	Etoposide, cyclophopshamide, cytarabine	✓	✓	cytara bine only	✓ cytarabine only	✓ cytarabine only	✓ cytarabine only	N
week 22-24	Dexamethasone, 6MP, MTX, Vincristine	✓	✓	✓	✓	✓	✓	N
week 25	6MP,HD po MTX	✓	✓					N
week 26-7	6MP, MTX	✓	✓					N
week 28	Etoposide, cyclophosphamide, Cytarabine, MTX Tioguanine	✓	✓	✓ cytara bine only	✓ cytarabine only	✓ cytarabine only	✓ cytarabine only	N
week 29	Etoposide, cyclophopshamide, cytarabine	✓	✓	cytara bine only	✓ cytarabine only	✓ cytarabine only	✓ cytarabine only	N
<b>Phase 6</b> courses 1-7	vincristine, dexamethasone 6MP MTX	✓	✓	cytara bine only	✓ cytarabine only	✓ cytarabine only	✓ cytarabine only	N
course 8	vincristine, dexamethasone 6MP MTX	✓	✓	✓ vinc & dex	✓ vinc & dex	✓ vinc & dex	✓ vinc & dex	N
<b>intrathecal</b>		✓ theatres	✓					Y

GOSH Relapsed/Refractory ALL  
August 2015

Refractory ALL								
FLA	Fludarabine, Cytarabine	✓						
Nelarabine	Nelarabine	✓						CDF cohort application
Clofarabine, Etoposide, Cyclophosphamide	Clofarabine, Etoposide, Cyclophosphamide	✓						CDF cohort application for clofarabine

--	--	--

Diagnosis		Place of delivery									
		PTC	Safari Day care	Low Risk	POSCU Level 1	POSCU Level 2	POSCU Level 3	Chemocare	TX guideline	Review date	Comments
<b>Acute Myeloid Leukaemia- Treatment guideline</b>											
ADE 10+3+5	Etoposide, Cytarabine, Daunorubicin	✓						Y	GOSH Guideline for the treatment of AML AND High risk MDS V4.1	Mar-16	
ADE 8+3+5	Etoposide, Cytarabine, Daunorubicin	✓						Y			
FLA-Ida	Cytarabine, Fludarabine Idarubicin	✓						Y			
FLA no GCSF	Cytarabine, Fludarabine	✓						Y			
HiDAC	Cytarabine 3g/m2	✓						Y			
Intrathecal Triple	Cytarabine, methotrexate, hydrocortisone	✓	✓					Y			

<b>Acute Myeloid Leukaemia in Down Syndrome ML-DS</b>												
AIE	Etoposide, Cytarabine, Idarubicin	✓							Y	ML-DS 2007 UK final version March 2014	N/A	
AI	Cytarabine, Idarubicin	✓						Y				
haM	Cytarabine, Mitozantrone	✓						Y				
HA	Cytarabine 3g/m2	✓						Y				
Intrathecal cytarabine	Cytarabine	✓						Y				
<b>Transient Abnormal myelopoiesis (TAM)</b>												
GOSH protocol	Low dose Cytarabine	✓							Y	GOSH Guideline for the treatment of TAM in babies with Down Syndrome V1 July 2010	TBC	
<b>Relapsed Acute Myeloid Leukaemia</b>												
FLA no GCSF	Cytarabine, Fludarabine	✓							Y	Guidelines for the management of relapsed non APL in children August 2010	TBC	
FLA -DaunoXome no GCSF	Cytarabine, Fludarabine, DaunoXome	✓							Y			

Diagnosis		Place of delivery									Comments
		PTC	Safari Day care	Low Risk	POSCU Level 1	POSCU Level 2	POSCU Level 3	Chemocare	Tx Guideline	Review date	
<b>Acute Promyelocytic Leukaemia</b>											
<b>Low risk - Induction</b>											
Daily ATO	Arsenic Trioxide	✓	✓					N	GOSH guideline for the treatment of APL V1 Sep 2015	Sep-17	Check funding arrangements
ATRA	Tretinoin	✓	✓					N			
Prednisolone D1-14	Prednisolone	✓	✓					N			
<b>Low risk - Consolidation</b>											
5/7 X 4 x4 ATO	Arsenic Trioxide	✓	✓					N	GOSH guideline for the treatment of APL V1 Sep 2015	Sep-17	Check funding arrangements
ATRA 2 weeks on, two weeks off for 7 cycles	Tretinoin	✓	✓					N			
Intrathecal cytarabine	Cytarabine x2	✓	✓					N			
<b>High Risk - Induction</b>											
Daily ATO	Arsenic Trioxide	✓	✓					N	GOSH guideline for the treatment of APL V1 Sep 2015	Sep-17	Check funding arrangements
Idarubicin x3	Idarubicin	✓						N			
Prednisolone D1-14	Prednisolone	✓	✓					N			

High Risk - Consolidation												
5/7 X 4 x4 ATO	Arsenic Trioxide	✓	✓						N	GOSH guideline for the treatment of APL V1 Sep 2015	Sep-17	Check funding arrangements
ATRA 2 weeks on, two weeks off for 7 cycles	Tretinoin	✓	✓						N			
Intrathecal cytarabine	Cytarabine x3	✓	✓						N			

Diagnosis		Place of delivery									Comments
		PTC	Safari Day care	Low Risk	POSCU Level 1	POSCU Level 2	POSCU Level 3	Chemocare	Tx Guideline	Review date	
<b>Chronic Myeloid Leukaemia</b>											
Hydroxycarbamide	Hydroxycarbamide	✓	✓					N	Recommendations for the management of CML in children and young people <18 years lbfm	N/A	
Imatinib	Imatinib	✓	✓					N			
<b>Chronic Myeloid Leukaemia- second line treatment</b>											
Dasatinib	Dasatinib	✓	✓					N			
<b>Juvenile Myelomonocytic Leukaemia (JMML)</b>											
Mercaptopurine	Mercaptopurine	✓	✓					N	N	N/A	
Cytarabine, Etoposide	Cytarabine, Etoposide	✓						N	N	N/A	
Azacitidine	Azacitidine	✓	✓					N	GOSH guideline for azacitidine for the treatment of Myelo-dysplastic syndromes in children V1 November 2015	Nov-17	

Diagnosis		Place of delivery											
		PTC	Safari Day care	Low Risk	POSCU Level 1	POSCU Level 2	POSCU Level 3	Chemocare	Tx Guideline	Review date	Comments		
<b>B-NHL CCLG guidelines - 1st line</b>													
<b>Group A</b>													
COPAD	Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone	✓						Y	UKCCSG NHL group Guideline for the management of Burkitt/burkitt like B large cell non hodgkins lymphoma July 2003	N/A			
<b>Group B</b>													
COP	Cyclophosphamide, Prednisolone, Vincristine	✓						Y					
COPADM 1+2	Cyclophosphamide, Prednisolone, Vincristine, Doxorubicin, Methotrexate	✓						Y					
CYM 1+2	Cytarabine, methotrexate	✓						Y					
<b>Group C</b>													
COP	Cyclophosphamide, Prednisolone, Vincristine	✓						Y					
COPADM 1	Cyclophosphamide, Prednisolone, Vincristine, Doxorubicin, Methotrexate	✓						Y					
COPADM 2	Cyclophosphamide, Prednisolone, Vincristine, Doxorubicin, methotrexate	✓						Y					

GOSH B-NHL August 2015

CYVE 1+2 CNS +VE	Cytarabine, Etoposide, Methotrexate	✓						Y	UKCCSG NHL group Guideline for the management of Burkitt/burkitt like B large cell non hodgkins lymphoma July 2003	N/A			
Maintenance C1	Vincristine, Prednisolone, Methotrexate, Cyclophosphamide, Doxorubicin	✓						Y					
Maintenance C2	Cytarabine, Etoposide	✓					✓	Y					
Maintenance C3	Vncristine, Prednisolone, Cyclophosphamide, Doxorubicin	✓						Y					
Maintenance C4	Cytarabine, Etoposide	✓					✓	Y					
<b>Intrathecal Treatment</b>													
MTX and HYD	Methotrexate, hydrocortisone	✓	✓					Y					
CYT and HYD	Cytarabine, hydrocortisone	✓	✓					Y					
Triple	Methotrexate, hydrocortisone, cytarabine	✓	✓					Y					
<b>B-NHL 2nd Line</b>													
Rituximab		✓	✓					N	GOSH guideline for the use of rituximab in Haematology/ Oncology/ BMT	Sep-17			
ICE	Ifosfamide, Cytarabine, Etoposide	✓						N	As above	N/A			
BEAM	Carmustine, Melphalan, Etoposide, Cytarabine	✓						N					

GOSH Approved Regimens

B-NHL August 2015

Approved by Dr Eslje van Rijswijk on behalf of the Haematology MDT

GOSH B-NHL August 2015

GRAB	Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, IV Methotrexate, Etoposide, Tioguanine, Cytarabine, Intrathecal Methotrexate	✓								GOSH GRAB guideline Version 1.1	Feb-18	
<b>Inter - B NHL Ritux 2010 Trial IMP-Rituximab</b>												
<b>Group B</b>												
COP	Cyclophosphamide, Prednisolone, Vincristine	✓							Y	Inter B-NHL Ritux 2010 Protocol V3 20.03.15	N/A	
COPADM 1 & 2 (+ rituximab for randomised patients)	Cyclophosphamide, Prednisolone, Vincristine, Doxorubicin, Methotrexate	✓							Y			
CYM 1& 2 (+ rituximab for randomised patients)	Cytarabine, methotrexate	✓							Y			
COP	Cyclophosphamide, Prednisolone, Vincristine	✓							Y	Inter B-NHL		
COPADM 1 (+ rituximab for randomised patients)	Cyclophosphamide, Prednisolone, Vincristine, Doxorubicin, Methotrexate	✓							Y			
COPADM 2 (+ rituximab for randomised patients)	Cyclophosphamide, Prednisolone, Vincristine, Doxorubicin, methotrexate	✓							Y			

GOSH B-NHL August 2015

CYVE 1 & 2 (+ rituximab for randomised patients)	Cytarabine, Etoposide,	✓							Y	Ritux 2010 Protocol V3 20.03.15	N/A			
HDMTX - TIT (CNS +ve, CNS -ve only)	Methotrexate	✓							Y					
M1	Vincristine, Prednisolone, Methotrexate, Cyclophosphamide, Doxorubicin	✓							Y					
M2	Cytarabine, Etoposide	✓							Y					
<b>Group C3</b>														
COP	Cyclophosphamide, Prednisolone, Vincristine	✓							Y	Inter B-NHL Ritux 2010 Protocol V3 20.03.15	N/A			
COPADM 1 (+ rituximab for randomised patients)	Cyclophosphamide, Prednisolone, Vincristine, Doxorubicin, Methotrexate	✓							Y					
COPADM 2 (+ rituximab for randomised patients)	Cyclophosphamide, Prednisolone, Vincristine, Doxorubicin, methotrexate	✓							Y					
IT- CYVE/MTX (+ rituximab for randomised patients)	Cytarabine, Etoposide, Methotrexate	✓							Y					
IT- CYVE (+ rituximab for randomised patients)	Cytarabine, Etoposide,	✓							Y					

GOSH B-NHL August 2015

M1	Vincristine, Prednisolone, Methotrexate, Cyclophosphamide, Doxorubicin	✓							Y		
M2	Cytarabine, Etoposide	✓							Y		
<b>Intrathecal Treatment</b>											
MTX and HYD	Methotrexate, hydrocortisone	✓	✓						Y	Inter B-NHL Ritux 2010 Protocol V3 20.03.15	N/A
CYT and HYD	Cytarabine, hydrocortisone	✓	✓						Y		
Triple	Methotrexate, hydrocortisone, cytarabine	✓	✓						Y		

Diagnosis		Place of delivery									
		PTC	Safari Day care	Low Risk	POSCU Level 1	POSCU Level 2	POSCU Level 3	Chemocare	Tx guideline	Review date	Comments
<b>Anaplastic Large Cell Lymphoma - ALCL CCLG guidelines</b>											
Pre-phase	Dexamethasone, Cyclophosphamide	✓						Y	NHL 2000 06	N/A	
Course AM	Methotrexate, Ifosfamide, Cytarabine, Etoposide	✓						Y			
Course BM	Methotrexate, Dexamethasone, Cyclophosphamide,	✓						Y			
Triple Intrathecal	Cytarabine, methotrexate, hydrocortisone	✓	✓								
<b>Anaplastic Large Cell Lymphoma - Second line therapy</b>											
Vinblastine		✓	✓					N	N		
Brentuximab		✓						N	N		Cancer drug fund cohort application

GOSH Approved regimens

ALCL August 2015

Approved by Dr Elsje van Risjswijk on behalf of the Haematology MDT

Diagnosis	Place of delivery										
	PTC	Safari Day care	Low Risk	POSCU Level 1	POSCU Level 2	POSCU Level 3	Chemocare	Tx Guideline	Review date	Comments	
<b>Haemophagocytic Langerhans Cell Histiocytosis</b>											
	Dexamethasone	✓	✓			✓	N	HLH 94	N/A		
	Etoposide	✓	✓		✓	✓	N				
	Intrathecal methotrexate	✓	✓				N				